|
|
Vaccine Detail
|
F2T-antigen-MUC1-TTox vaccine |
| Vaccine Information |
- Vaccine Name: F2T-antigen-MUC1-TTox vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Conjugate vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: MUC1 (Hoffmann-Röder et al., 2010)
- Immunization Route: subcutaneous injection
- Description: A synthetic conjugate vaccine consisting of MUC1 tandem-repeat glycopeptides bearing either natural Thomsen-Friedenreich (T-antigen) or 6,6'-difluorinated T-antigen saccharide side chains, chemically conjugated to tetanus toxoid carrier protein via squaric acid linker with triethylene glycol spacer. Glycopeptides were synthesized by Fmoc solid-phase chemistry on Tentagel resin. Vaccine loading achieved >20 glycopeptide molecules per tetanus toxoid molecule. The T-antigen represents a tumor-associated carbohydrate antigen characteristically overexpressed on epithelial cancer cells with truncated, premature glycosylation compared to normal cells. In balb/cJ mice immunized with CFA (initial) and IFA (boosters at 21 days), 6/6 mice responded (vs. 1/3 in previous transgenic studies); >25x stronger vs. MUC1-ovalbumin-T-cell-epitope vaccines, >100x vs. Pam3Cys-lipopeptide-MUC1 vaccines; IgG1-dominant, minimal IgM; strong MCF-7 binding; recognized natural + fluorinated antigens. T-antigen vaccine: ~80,000 titers, some IgG2a,b. F2T-antigen vaccine: ~40,000 titers, increased IgG2a,b. Induced antibodies demonstrated strong MCF-7 epithelial tumor cell binding at 1000-fold serum dilution with selective neutralization by corresponding MUC1 glycopeptides but not unrelated MUC4 peptides, confirming tumor-selective recognition. Cross-recognition observed: antibodies from both vaccines bound natural and fluorinated antigens equally; additionally recognized related tumor antigens including sialyl-Tn and 2,6-sialyl-T structures on MUC1 sequences. The 6,6'-fluorine substitution maintained full immunogenicity and selectivity with potential advantage of enhanced enzymatic stability for long-term cancer treatment applications. Successfully overcame natural immune tolerance against self-associated tumor antigens. Tetanus toxoid carrier enables potential human application based on established clinical safety profile (Hoffmann-Röder et al., 2010).
|
| Host Response |
|
|
| References |
Hoffmann-Röder et al., 2010: Hoffmann-Röder A, Kaiser A, Wagner S, Gaidzik N, Kowalczyk D, Westerlind U, Gerlitzki B, Schmitt E, Kunz H. Synthetic antitumor vaccines from tetanus toxoid conjugates of MUC1 glycopeptides with the Thomsen-Friedenreich antigen and a fluorine-substituted analogue. Angewandte Chemie (International ed. in English). 2010; 49(45); 8498-8503. [PubMed: 20878823].
|
|
